NCT02977117View on ClinicalTrials.gov

The Effect of Increasing Dialysate Magnesium on Calcification Propensity in Subjects on Haemodialysis

PHASE2CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

June 30, 2017

Study Completion Date

June 30, 2017

Conditions
Endstage Renal Disease
Interventions
OTHER

Dialysate magnesium (1.0 mmol/L)

Dialysate magnesium will be increased from 0.5 mmol/L to 1.0 mmol/L for 4 weeks after which subjects will return to dialysate magnesium 0.5 mmol/L for 2 weeks observation.

OTHER

Dialysate magnesium (0.5 mmol/L)

Dialysate magnesium will be maintained at 0.5 mmol/L for the duration of the trial.

Trial Locations (1)

3400

Iain Bressendorff, Hillerød

All Listed Sponsors
lead

Iain Bressendorff

OTHER

NCT02977117 - The Effect of Increasing Dialysate Magnesium on Calcification Propensity in Subjects on Haemodialysis | Biotech Hunter | Biotech Hunter